Skip to main content
. 2021 Jan 1;11(1):304–315. doi: 10.7150/thno.45540

Figure 4.

Figure 4

Treatment with 177Lu-DOTA-Y003 increases tumor-infiltrating lymphocytes and upregulates PD-L1 expression in tumors. A. Percentage of PD-L1 neoplastic cells (CD45-/PD-L1), CD8+ T cells, CD4+ T cells and regulatory T cells in tumors after the indicated treatment. B. Representative fluorescent images of the immunofluorescence staining of tumors.